pharma · Advanced or metastatic solid tumors · Waldenström's Macroglobulinemia
BeiGene
BeiGene clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US
- Founded
- 2010
- Employees
- 2,047
- Programs
- 14
- Drugs
- 19
- Patents
- 25
BeiGene projects
4 ClinicalTrials.gov programs sponsored by BeiGene.
BeiGene has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
OBINUTUZUMAB, Zanubrutinib
BeiGene
Relapsed/Refractory Follicular Lymphoma
1 trial -
Sitravatinib
BeiGene
Carcinoma, Hepatocellular
1 trial -
Surzebiclimab
BeiGene
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
1 trial -
Tislelizumab
BeiGene
Cervical Cancer
1 trial
Frequently asked questions
How many clinical projects does BeiGene have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.